NouvNeu 001
Alternative Names: Human dopaminergic progenitor cells; NouvNeu-001Latest Information Update: 04 Oct 2024
At a glance
- Originator iRegene Therapeutics
- Class Antiparkinsonians; Induced pluripotent stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Parkinson's disease
Most Recent Events
- 23 Aug 2024 iRegene Therapeutics initiates enrolment in a phase I trial for Parkinson's disease (In the elderly, In adults) in China (Parenteral) (NCT06608355)
- 24 Jun 2024 The US FDA approves an IND application for NouvNeu 001 in Parkinson's disease
- 24 Jun 2024 The US FDA approves clinical trial application for a phase I/II trial in Parkinson's disease